Replies to post #9293 on Funr (FUNR)

[benosufan]

Annual Report with highlights

http://www.otcmarkets.com/financialReportViewer?symbol=CUBV&id=116789

GROSS PROFIT 4th Q 2013 $ 8,434
NET PROFIT (LOSS)4th Q 2013 $ (198,901)

GROSS PROFIT FY2013 $ 14,725
NET PROFIT (LOSS) FY2013 $ (458,210)

Balance December 31, 2013 shares outstanding 83,086,259 Float 28,897,593Total since inception Paid in capital $4,367,291

Revenue

During the quarter ending December 31, 2013 the Company sold 2,020 cases of its all-natural energy juice product for $42,223 or $.88 per can. White Rose, Core Mark, and Fairway Markets, the Company’s main distributors, generated the sales pursuant to their wholesale agreement as did DSD Promoting, the Company’s South Florida distributor. The Company anticipates sales volume to experience steady growth with White Rose, DSD and other distributors for the duration of the fiscal year.
Total revenue during the year ended December 31, 2013 was $85,978 as compared to $43,755 for the year ended December 31, 2012 and represents a nearly 100% increase in sales from the previous year.

Comparing Revenues from previous quarter...NOTE: from last quarterly report...Revenue
During the quarter ending September 30, 2013 the Company sold 936 cases of its all-natural energy juice product for $25,347 or $1.12 per can.

Inventory consists primarily of beverages purchased and is stated at the lower of cost (first-in, first-out) or market value. As of December 31, 2013, the Company has produced approximately 22,657 cases of its product from its production runs in 2012 and 2013 (collectively referred to production run # 1). The Company currently has 9,411 cases of product on hand, which represents a current balance of $115,859 reflects the cost of aluminum cans, can tab ends and the ingredients for Cuba Beverage Juice, less the cost for the 2,020 cases sold in the current quarter for a cost of goods sold of $12.31 per case ($.51 per can), exclusive of freight costs.


During the fiscal quarter ending March 31, 2013, the Company sold 6.1 million shares of its restricted common stock at an average price of $.01 per share, which represents a reasonable discount to the average market price during the same period. The sale of the Company’s common stock was facilitated through a private placement memorandum and all issuances relating thereto are restricted from sale on the open market for a period of one year.

During the fiscal quarter ending June 30, 2013, the Company sold 1.25 million shares of its restricted common stock at an average price of $.02 per share, which represents a reasonable discount to the average market price during the same period. The sale of the Company’s common stock was facilitated through a private placement memorandum and all issuances relating thereto are restricted from sale on the open market for a period of one year.

During the fiscal quarter ending September 30, 2013, the Company sold 2,800,000 shares of its restricted common stock at an average price of $.05 per share, which represents a reasonable discount to the average market price during the same period. The sale of the Company’s common stock was facilitated through a private placement memorandum and all issuances relating thereto are restricted from sale on the open market for a period of one year.

During the fiscal quarter ending December 31, 2013, the Company did sold zero (0) shares of its common stock.

ITEM 4. ISSUANCE HISTORY
Events by the Issuer Resulting in Changes in Total Outstanding Shares for the Past Two Fiscal Years:
To the best knowledge of the present management of the Company, the list identified below identifies all events, in chronological order, that resulted in changes in total shares outstanding by the Company (1) within the two-year period ending on the last day of the Company’s most recent fiscal year and (2) since the last day of the Company’s most recent fiscal year.
For the three-month period ending December 31, 2013, the Company issued no shares of common stock.
For the three-month period ending September 30, 2013, there were 3,500,000 total shares of restricted common stock issued by the Company. The following is a breakdown of those issuances:
On August 16, 2013, a total of 1,300,000 restricted shares of common stock were issued to two investors who subscribed to our PPM.
On September 9, 2013, a total of 1,500,000 restricted shares of common stock were issued to two investors who subscribed to our PPM.
During the third quarter of 2013, the company issued 700,000 restricted common shares for services rendered to various consultants in connection with securing distribution agreements for the Company’s product line.
For the period ending June 30, 2013, there were 1,950,000 total shares of restricted common stock issued by the Company. The following is a breakdown of those issuances:
On May 1, 2013, 500,000 restricted shares of common stock were issued to Anthony Procopio, Jr. in connection with services rendered on behalf of the Company regarding distribution and marketing of Company products in the northeastern region of the United States.
On May 1, 2013, 200,000 restricted shares of common stock were issued to Consumer Assistance Program, Inc. in connection with services rendered on behalf of the Company for marketing products on the west coast.
4
On June 28, 2013, 1,250,000 restricted shares of common stock were issued to two investors who subscribed to our PPM.
For the period ending March 31, 2013, there were 11,270,000 shares issued for services rendered and also under the terms of a private placement offered by the Company, 170,000 of which were issued to third parties as payment for services rendered to the Company. The following is a breakdown of those issuances:
On January 24, 2013, 5,000,000 restricted shares of common stock were issued to the Company’s Chief Executive Officer for services rendered to the Company.
On February 20, 2013, there were 6,100,000 shares of common stock issued to various investors who subscribed to our private placement memorandum (“PPM”).
On February 21, 2013, there were 70,000 restricted shares of common stock issued for services rendered relating to capital raising efforts.
On March 22, 2013, there were 100,000 restricted shares of common stock issued for the purposes of assisting in the distribution of the Company’s products.
For the year ending December 31, 2012, there were 10,180,000 restricted shares issued under the terms of the private placement offered by the Company. A more detailed issuance history can found on the Company’s most Annual Report for the fiscal year ended December 31, 2012 filed with OTCMarkets.com on March 30, 2013, incorporated by reference herein.

[benosufan]

Overall 17% profit margin..not going to make a big dent in this operating loss for a long time unless they increase sales by 97%

Operating loss for 2013 is ($458,210) NOTE: even worse was the loss for 4th Q 2013 ($198,901) and that was with more than double amount of cases sold the previous quarter.

To make $458,210 in net profit at 17% profit margin they would need $2,695,352 in revenues.

Alex needs to massively increase revenues if he wants CUBV to become profitable. I don't see them trimming overhead...they are trying to add to it by hiring more employees.

Even though he doubled revenues in 2013 they were only 86k....I expected much more than this considering they are in so many markets. I guess the product is just not selling...or is it ineffective/lack of promotion? I know it's a start up company...let's see what they do in 2014. Meanwhile, I foresee a sell off in the near future...probably involving a paid promo again.